Article
Oncology
Jessika Contreras, Amar Srivastava, Pamela Samson, Todd DeWees, Ramaswamy Govindan, Maria Q. Baggstrom, Daniel Morgensztern, Michael Roach, Shahed N. Badiyan, Jeffrey Bradley, Saiama Waqar, Clifford Robinson
Summary: The study aimed to evaluate the maximum tolerated dose of hypofractionated proton beam radiation therapy with concurrent weekly carboplatin/paclitaxel in patients with stage II-III non-small cell lung cancer. The results showed that the treatment was acutely well tolerated, with high rates of locoregional control and overall survival. Late serious adverse events were noted in some patients outside of the dose-escalation window.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
S. Senan, M. Ozguroglu, D. Daniel, A. Villegas, D. Vicente, S. Murakami, R. Hui, C. Faivre-Finn, L. Paz-Ares, Y. L. Wu, H. Mann, P. A. Dennis, S. J. Antonia
Summary: Durvalumab improves progression-free survival and overall survival in patients with or without stage IIIA-N2 non-small-cell lung cancer (NSCLC). Further research is needed to determine the optimal treatment approach for patients who are deemed operable.
Article
Oncology
Takefumi Komiya, Shinkichi Takamori, Gregory Wilding
Summary: This study suggests that adjuvant radiation may still play a role in improving overall survival in patients with persistent N2 disease after neoadjuvant chemotherapy. Adjuvant radiation may have a beneficial effect in patients who are not downstaged to pN0-1.
RADIOTHERAPY AND ONCOLOGY
(2022)
Review
Oncology
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang
Summary: Despite advancements in diagnosis and treatment, lung cancer mortality remains high. This review provides an overview of current diagnostic methods and therapies for non-small cell lung cancer, serving as a guide for clinicians.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Bradford S. Hoppe, Romaine C. Nichols, Stella Flampouri, Mark Pankuch, Christopher G. Morris, Dat C. Pham, Pranshu Mohindra, William F. Hartsell, Nasiruddin Mohammed, Brian H. Chon, Larry L. Kestin, Charles B. Simone, Charles B. Simone
Summary: This study aimed to evaluate the impact of hypofractionated proton therapy with concurrent chemotherapy on overall survival in patients with locally advanced non-small cell lung cancer. The results showed promising survival rates at 1-year and 3-year follow-up, with minimal toxic effects.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Article
Oncology
Fabrice Barlesi, Pascale Tomasini, Maryam Karimi, Stefan Michiels, Judith Raimbourg, Catherine Daniel, Henri Janicot, Anne Madroszyk, Clarisse Audigier-Valette, Elisabeth Quoix, Julien Mazieres, Denis Moro-Sibilot, Eric Dansin, Olivier Molinier, Hugues Morel, Eric Pichon, Alexis Cortot, Josiane Otto, Francois Chomy, Pierre-Jean Souquet, Nicolas Cloarec, Etienne Giroux-Leprieur, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Valery Attignon, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Filippo Gustavo Dall'Olio, Marta Jimenez, Jean-Charles Soria, Benjamin Besse
Summary: Targeted therapies and immune checkpoint blockers have revolutionized the treatment of non-small cell lung cancer. This study investigated the use of targeted therapies and immune checkpoint blockers as maintenance therapy based on molecular characterization. The results showed no significant differences in progression-free survival between targeted therapies and standard-of-care, and immune checkpoint blockers showed enhanced benefits in patients with PD-L1 >= 1%.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Janna Berg, Christina Ramberg, Jon Olav Sulheim Haugstvedt, May-Bente Bengtson, Anne-Marie Gabrielsen, Odd Terje Brustugun, Ann Rita Halvorsen, Aslaug Helland
Summary: This study investigated changes in pulmonary function, symptoms, and radiological signs of pneumonitis in patients receiving stereotactic body radiation therapy for early-stage non-small cell lung cancer. Symptomatic radiation pneumonitis occurred in 18% of patients, while asymptomatic pneumonitis was observed in 39% based on radiology. Early decreases in FEV1 and DLCO may indicate the development of symptomatic radiation pneumonitis, which could be predicted by doses to critical lung volumes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Janna Berg, Ann Rita Halvorsen, May-Bente Bengtson, Morten Lindberg, Bente Halvorsen, Pal Aukrust, Aslaug Helland, Thor Ueland
Summary: This study found that T cell activation and exhaustion markers sCD25 and sTIM-3 are enhanced in NSCLC patients developing radiation pneumonitis (RP) and are associated with poor survival.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Anasse Nounsi, Joseph Seitlinger, Charlotte Ponte, Julien Demiselle, Ysia Idoux-Gillet, Erwan Pencreach, Michele Beau-Faller, Veronique Lindner, Jean-Marc Balloul, Eric Quemeneur, Helene Burckel, Georges Noel, Anne Olland, Florence Fioretti, Pierre-Emmanuel Falcoz, Nadia Benkirane-Jessel, Guoqiang Hua
Summary: Radiation therapy and platinum-based chemotherapy are common treatments for lung cancer patients. Factors such as the patient's physical state and tumor heterogeneity contribute to the low overall survival rate in lung cancer. This study demonstrates that a patient-derived tumoroid model can be used to predict the efficacy of radiation therapy and cisplatin-based chemotherapy in non-small-cell lung cancer, and the results are correlated to clinical outcomes.
Article
Cardiac & Cardiovascular Systems
Kaitlin McLaughlin, Kay See Tan, Joe Dycoco, Monica F. Chen, Jamie E. Chaft, Nikhil P. Mankuzhy, Andreas Rimner, Rania G. Aly, Rachel E. Fanaroff, William D. Travis, Mark Bilsky, Manjit Bains, Robert Downey, James Huang, James M. Isbell, Daniela Molena, Bernard J. Park, David R. Jones, Valerie W. Rusch
Summary: A multidisciplinary care paradigm, involving medical and radiation oncology, as well as spine neurosurgery, can improve surgical outcomes for Pancoast tumors. Spine neurosurgery allows for the resection of transverse processes and vertebral bodies. This treatment approach is associated with a high rate of R0 resection, complete response, and major pathologic response. The prognosis of cT3 and cT4 tumors is similar.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
(2023)
Article
Oncology
Nasser K. Altorki, Timothy E. McGraw, Alain C. Borczuk, Ashish Saxena, Jeffrey L. Port, Brendon M. Stiles, Benjamin E. Lee, Nicholas J. Sanfilippo, Ronald J. Scheff, Bradley B. Pua, James F. Gruden, Paul J. Christos, Cathy Spinelli, Joyce Gakuria, Manik Uppal, Bhavneet Binder, Olivier Elemento, Karla Ballman, Silvia C. Formenti
Summary: The combination of neoadjuvant durvalumab and stereotactic body radiotherapy in early-stage NSCLC patients shows a high major pathological response rate and is well tolerated, suggesting its potential in treatment, although it comes with certain adverse events.
Review
Pharmacology & Pharmacy
Zaid Sirhan, Rawan Alojair, Anita Thyagarajan, Ravi P. Sahu
Summary: Lung cancer is a major malignancy globally, with NSCLC being the most common type. PTEN, a tumor suppressor gene, plays a critical role in regulating cancer growth and its dysfunction is associated with poor prognosis in lung cancer patients. PTEN has been explored as a promising target for anti-cancer agents, as it can interact with multiple signaling pathways to devise effective treatment options for NSCLC.
Review
Oncology
Suli Zhang, Qian Sun, Feng Cai, Hui Li, Yufu Zhou
Summary: This review analyzes treatment strategies and prognostic factors for patients with oligometastatic non-small cell lung cancer (OM-NSCLC), with a focus on the importance of local ablation therapy (LAT) as a significant treatment component.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Sung Jun Ahn, Hyeokjin Kwon, Jun Won Kim, Goeun Park, Mina Park, Bio Joo, Sang Hyun Suh, Yoon Soo Chang, Jong-Min Lee
Summary: This study aims to investigate the association between the risk of brain metastases (BM) in the hippocampal-avoidance region (HAR) and the stage and molecular status of non-small cell lung cancer (NSCLC) patients. The results suggest that patients with extra-cranial metastases are more likely to have BM in the HAR.
FRONTIERS IN ONCOLOGY
(2022)
Article
Clinical Neurology
Matt Lechner, Yoko Takahashi, Mario Turri-Zanoni, Marco Ferrari, Jacklyn Liu, Nicholas Counsell, Davide Mattavelli, Vittorio Rampinelli, William Vermi, Davide Lombardi, Rami Saade, Ki Wan Park, Volker H. Schartinger, Alessandro Franchi, Carla Facco, Fausto Sessa, Simonetta Battocchio, Tim R. Fenton, Francis M. Vaz, Paul O'Flynn, David Howard, Paul Stimpson, Simon Wang, S. Alam Hannan, Samit Unadkat, Jonathan Hughes, Raghav Dwivedi, Cillian T. Forde, Premjit Randhawa, Simon Gane, Jonathan Joseph, Peter J. Andrews, Manas Dave, Jason C. Fleming, David Thomson, Tianyu Zhu, Andrew Teschendorff, Gary Royle, Christopher Steele, Joaquin E. Jimenez, Jan Laco, Eric W. Wang, Carl Snyderman, Peter D. Lacy, Robbie Woods, James P. O'Neill, Anirudh Saraswathula, Raman Preet Kaur, Tianna Zhao, Murugappan Ramanathan, Gary L. Gallia, Nyall R. London, Quynh-Thu Le, Robert B. West, Zara M. Patel, Jayakar V. Nayak, Peter H. Hwang, Mario Hermsen, Jose Llorente, Fabio Facchetti, Piero Nicolai, Paolo Bossi, Paolo Castelnuovo, Amrita Jay, Dawn Carnell, Martin D. Forster, Diana M. Bell, Valerie J. Lund, Ehab Y. Hanna
Summary: This study retrospectively analyzed clinical data from 505 cases of sinonasal mucosal melanoma (SNMM). It found that further stratifying the T3 stage by sinus involvement has a high predictive value for prognosis. Adjuvant radiotherapy can improve survival rates, and immune checkpoint inhibitors show potential benefits for the treatment of recurrent, persistent, or metastatic disease.
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE
(2023)
Article
Oncology
Maura L. Gillison, Robert L. Ferris, Jonathan Harris, A. Dimitrios Colevas, Loren K. Mell, Christina Kong, Richard C. Jordan, Kevin L. Moore, Minh-Tam Truong, Claudia Kirsch, Arnab Chakravarti, Dukagjin M. Blakaj, David A. Clump, James P. Ohr, John F. Deeken, Michael F. Gensheimer, Nabil F. Saba, Jennifer A. Dorth, David I. Rosenthal, Rom S. Leidner, Randall J. Kimple, Mitchell Machtay, Walter J. Curran, Pedro Torres-Saavedra, Quynh Thu Le
Summary: A study found that the concurrent administration of nivolumab with (chemo)radiation is safe and effective for newly diagnosed patients with intermediate and high-risk head and neck squamous cell carcinoma (HNSCC).
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
Christina I. Tsien, Stephanie L. Pugh, Adam P. Dicker, Jeffrey J. Raizer, Martha M. Matuszak, Enrico C. Lallana, Jiayi Huang, Ozer Algan, Nimisha Deb, Lorraine Portelance, John L. Villano, John T. Hamm, Kevin S. Oh, Arif N. Ali, Michelle M. Kim, Scott M. Lindhorst, Minesh P. Mehta
Summary: This study evaluated whether reirradiation (re-RT) and concurrent bevacizumab (BEV) improve overall survival (OS) and/or progression-free survival (PFS) compared to BEV alone in recurrent glioblastoma (GBM). The results showed that the combination of re-RT and BEV significantly improved PFS, but had no difference in OS.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Li Guan, Dhanya K. Nambiar, Hongbin Cao, Vignesh Viswanathan, Shirley Kwok, Angela B. Hui, Yuan Hou, Rachel Hildebrand, Rie von Eyben, Brittany J. Holmes, Junfei Zhao, Christina S. Kong, Nathan Wamsley, Weiruo Zhang, Michael B. Major, Seung W. Seol, John B. Sunwoo, D. Neil Hayes, Maximilian Diehn, Quynh-Thu Le
Summary: Radiotherapy is a primary treatment for head and neck squamous cell carcinoma (HNSCC), but there is currently no reliable biomarker for predicting radioresistance. This study found that mutations in the NFE2L2 gene are associated with higher rates of locoregional failure in HNSCC patients treated with surgery and (chemo)radiotherapy. NFE2L2 mutations lead to radioresistance through Nrf2 activation, but this can be overcome by the glutaminase inhibitor CB-839.
Article
Oncology
Jimmy J. Caudell, Pedro A. Torres-Saavedra, David I. Rosenthal, Rita S. Axelrod, Phuc Felix Nguyen-Tan, Eric J. Sherman, Randal S. Weber, James M. Galvin, Adel K. El-Naggar, Andre A. Konski, Michelle I. Echevarria, Neal E. Dunlap, George Shenouda, Anurag K. Singh, Jonathan J. Beitler, Adam Garsa, James A. Bonner, Adam S. Garden, Ozer Algan, Jonathan Harris, Quynh-Thu Le
Summary: NRG Oncology conducted a phase 3 trial to test the impact of combining cisplatin and radiation or cetuximab and radiation on the overall survival of patients with locally advanced head and neck carcinoma. After a follow-up of over 10 years, the addition of cetuximab did not improve patient outcomes, regardless of p16 status.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Editorial Material
Oncology
Claire C. Baniel, Daniella Klebaner, Beth M. Beadle, Sara E. Beltran Ponce, Vinita Takiar, Iris C. Gibbs, Scott G. Soltys, Hilary P. Bagshaw, Daniel T. Chang, Quynh-Thu Le, Erqi L. Pollom
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Oncology
W. K. Jacky Lam, Ann D. King, Jacob A. Miller, Zhiwei Liu, Kelly J. Yu, Melvin L. K. Chua, Brigette B. Y. Ma, Ming Yuan Chen, Benjamin A. Pinsky, Pei-Jen Lou, John K. S. Woo, Wan-Lun Hsu, Julia Simon, Denise L. Doolan, Tim Waterboer, Edwin P. Hui, Hui Li, Raymond K. Tsang, Kenneth C. W. Wong, Julian P. Goh, Alexander C. Vlantis, Qi Yong Ai, Lun M. Wong, Victor Abdullah, Jin Ching Lin, Chien-Jen Chen, Ruth M. Pfeiffer, Quynh-Thu Le, Anne W. M. Lee, Mingfang Ji, Sumei Cao, Jun Ma, Anthony T. C. Chan, K. C. Allen Chan, Allan Hildesheim
Summary: A meeting of experts in November 2021 discussed the performance and cost-effectiveness of EBV-based approaches for screening early stage nasopharyngeal carcinoma. Both serum EBV antibody and plasma EBV DNA testing methods were found to be favorable. Additionally, the use of MRI was recommended to increase the sensitivity of NPC detection without greatly impacting the cost-effectiveness of the screening program.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2023)
Editorial Material
Oncology
Brigette B. Y. Ma, Quynh Thu Le
Summary: In this study, the authors present the results of a phase III clinical trial, showing the survival benefit of combining PD-1 inhibitors and chemotherapy in nasopharyngeal cancer. They also identify hot and cold tumor signatures through gene expression analysis, which have prognostic and predictive significance.
Article
Oncology
Adam S. Garden, Jonathan Harris, Avraham Eisbruch, K. S. Clifford Chao, William H. Morrison, Paul M. Harari, Todd Allen Swanson, Christopher U. Jones, Sue S. Yom, Sharon A. Spencer, Rufus Scrimger, George Shenouda, Monica Shukla, Harold Y. Lau, Michelle Mierzwa, Pedro Torres-Saavedra, Quynh Thu Le
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Medicine, General & Internal
Nancy Y. Lee, Jonathan Harris, John Kim, Adam Garden, James Mechalakos, David G. Pfister, Anthony T. C. Chan, Kenneth Hu, A. Dimitrios Colevas, Steven Frank, George Shenouda, Voichita Bar-Ad, John N. Waldron, Paul M. Harari, Adam Raben, Pedro Torres-Saavedra, Quynh-Thu Le
Summary: The study aimed to assess the long-term toxic effects and clinical outcomes associated with adding bevacizumab, a vascular endothelial growth factor inhibitor, to standard chemoradiation for patients with nasopharyngeal carcinoma (NPC). The results showed favorable long-term outcomes and no severe adverse events when using bevacizumab in combination with chemoradiation. Further investigation may be warranted.
Article
Oncology
Dhanya K. Nambiar, Vignesh Viswanathan, Hongbin Cao, Weiruo Zhang, Li Guan, Manish Chamoli, Brittany Holmes, Christina Kong, Rachel Hildebrand, Amanda Jeanette Koong, Rie von Eyben, Sylvia Plevritis, Lingyin Li, Amato Giaccia, Edgar Engleman, Quynh Thu Le
Summary: Galectin-1 increases STING stability in cancer cells that activates NF-kappa B signaling and CXCL2 expression to promote MDSC trafficking, which stimulates the generation of a premetastatic niche and facilitates metastatic progression.
Article
Computer Science, Artificial Intelligence
Yizheng Chen, Lequan Yu, Jen-Yeu Wang, Neil Panjwani, Jean-Pierre Obeid, Wu Liu, Lianli Liu, Nataliya Kovalchuk, Michael Francis Gensheimer, Lucas Kas Vitzthum, Beth M. Beadle, Daniel T. Chang, Quynh-Thu Le, Bin Han, Lei Xing
Summary: Defining the loss function is crucial for the success of deep learning modeling. Traditional loss functions treat all regions in the input image equally, but in reality, different regions have different prediction performance. To address this, we introduce a region-specific loss that assigns higher weightings to more difficult sub-regions for better learning.
IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE
(2023)
Article
Medicine, Research & Experimental
Callum Beach, David MacLean, Dominika Majorova, Stavros Melemenidis, Dhanya K. Nambiar, Ryan K. Kim, Gabriel N. Valbuena, Silvia Guglietta, Carsten Krieg, Mahnaz Darvish-Damavandi, Tatsuya Suwa, Alistair Easton, Lily V. S. Hillson, Ashley K. McCulloch, Ross K. McMahon, Kathryn Pennel, Joanne Edwards, Sean M. O'Cathail, Campbell S. Roxburgh, Enric Domingo, Eui Jung Moon, Dadi Jiang, Yanyan Jiang, Qingyang Zhang, Albert C. Koong, Trent M. Woodruff, Edward E. Graves, Tim Maughan, Simon J. A. Buczacki, Manuel Stucki, Quynh-Thu Le, Simon J. Leedham, Amato J. Giaccia, Monica M. Olcina
Summary: An immunosuppressive microenvironment in colorectal cancer hinders tumor T cell infiltration and decreases patient overall survival. This study identifies complement receptor C5aR1 as a potential druggable target to enhance radiotherapy response, even in tumors with immunosuppressive features. Furthermore, C5aR1 not only plays a role in the immune compartment but is also expressed on malignant epithelial cells, suggesting its tumor cell-specific functions. Targeting C5aR1 leads to increased tumor apoptosis without affecting normal tissues, indicating its primary role in regulating malignant cell fate.
JOURNAL OF CLINICAL INVESTIGATION
(2023)
Article
Oncology
Elaine Limkin, Pierre Blanchard, Benjamin Lacas, Jean Bourhis, Mahesh Parmar, Lisa Licitra, Quynh-Thu Le, Sue S. Yom, Catherine Fortpied, Johannes Langendijk, Jan B. Vermorken, Jacques Bernier, Jens Overgaard, Jonathan Harris, Jean-Pierre Pignon, Anne Auperin
Summary: This study investigated the impact of season of radiotherapy on the outcomes of head and neck squamous cell cancer patients. The results showed that the season of radiotherapy did not have any significant effect on patient outcomes.
RADIOTHERAPY AND ONCOLOGY
(2024)
Article
Oncology
Joanne B. Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A. Masters, George R. Blumenschein, Joe Y. Chang, Bo Lu, Adam P. Dicker, Jeffrey A. Bogart, Yolanda I. Garces, Samir Narayan, Clifford G. Robinson, Vivek S. Kavadi, Joel S. Greenberger, Christopher D. Koprowski, James Welsh, Elizabeth M. Gore, Robert M. Macrae, Rebecca Paulus, Jeffrey D. Bradley
Summary: Although overall survival advantage was not observed in KRAS-variant patients, there is a potential impact of cetuximab for this genetic subset of patients. In contrast, cetuximab seems to harm non-variant patients. These findings further support the importance of genetic patient selection in trials studying the addition of systemic agents to radiotherapy.
CANCER RESEARCH COMMUNICATIONS
(2023)